Phase II Apa-RP Study of Erleada Shows Promise in Treatment of Patients with High-Risk Localized Prostate Cancer Who Have Undergone Previous Radical Prostatectomy

Significant findings included a 100% biochemical recurrence-free rate at 24 months post-surgery in patients with high-risk localized prostate cancer.